Regulus filed a solicitation/recommendation statement on Schedule 14D-9 with the SEC, which includes, among other things, the recommendation of Regulus’s board of directors that Regulus’s stockholders ...

Novartis has slimmed down its clinical-stage ... We took that data to heart and really wanted to rethink how we approach our pipeline.” “So we made a significant, nearly 40%, reduction in ...

Despite some declining revenues from established brands, Novartis' pipeline and recent performance suggest continued growth, with double-digit revenue and income growth expected in 2024.

Farabursen adds to Novartis' existing pipeline of kidney disease drugs, including those acquired through its $3.5 billion buyout of Chinook Therapeutics in 2023. Novartis has recently received U.S ...

Novartis has showcased its pipeline at its annual meet-the-management day, where investors and analysts got to hear company leaders give an overview of its drug pipeline. CEO Vas Narasimhan said ...

Swiss pharma giant Novartis is re-entering the booming field of ageing research. It wants to develop a blockbuster drug in ...

While organic growth continues to drive business, NVS is focused on strategic bolt-in acquisitions to strengthen its pipeline ...

Novartis' drug segment is poised for steady cash flows driven by new pipeline products and existing drugs. Novartis' strategy to focus largely in areas of unmet medical need should strengthen the ...

The leading Metastatic Merkel Cell Carcinoma Companies such as Incyte Corporation, Merck, Pfizer, Millennium Pharmaceuticals ...

Novartis NOVN-0.13%decrease; red down pointing triangle agreed to acquire Blackstone Life Sciences’ Anthos Therapeutics for up to $3.08 billion to boost its cardiovascular-drug pipeline.

ZURICH, Nov 2 (Reuters) - Novartis (NOVN.S), opens new tab expects ... although a big challenge will be maintaining the pipeline of new medications. Narasimhan said he was confident the company ...